Myasthenia Gravis Treatment Market Insights:
Myasthenia Gravis Treatment Market is projected to be worth USD 4.23 Billion by 2030, registering a CAGR of 8.1% CAGR during the forecast period (2022-2030), the market was valued at USD 2.10 Billion in 2021. Medication has the largest market share among the treatments and is anticipated to hold the top spot throughout the projected period. In 2021 the hospital sector had the largest market share, and during the projected period it is anticipated to grow at the highest CAGR. North America had the highest market share in 2021 and is anticipated to continue to dominate the market during the forecast period.
Myasthenia Gravis Treatment Market Dynamics:
Myasthenia gravis is an autoimmune disease and muscle weakness is a common long-term symptom. The muscles that regulate the eyes and eyelids, facial emotions, chewing, swallowing, and speaking is the ones most frequently affected. However, it can impact the majority of bodily parts. Any age group can be affected, but often it first appears in women under 40 and men over 60.
Driver:
The increased use of immunotherapies, the acceptance of effective medications, the development of biologics, and raising awareness of rare diseases are the major market-driving drivers. Further, the increasing geriatric population is expected to boost the growth of the myasthenia gravis market.
Restraint:
The side effects of the medications used to treat the condition myasthenia gravis treatments market are expected to hamper the growth of the market. Patients with myasthenia gravis, for instance, have acute muscle cramping while using high-dose combinations of cholinesterase inhibitors (ChEIs) and calcineurin inhibitors (CNIs), such as Mestinon and Prograf. Therefore, it is anticipated that this factor will slow the market’s expansion for myasthenia gravis treatments.
COVID-19 Analysis of Myasthenia Gravis Treatment Market:
The global myasthenia gravis treatment market’s expansion was negatively impacted by the COVID-19 epidemic. Patients were very reluctant to undergo elective procedures like cataracts and reconstructive surgery as a result of the COVID-19 pandemic. As only urgent surgeries were carried out, trips to eye clinics and hospitals substantially decreased. Access to Eye Care during the COVID-19 Pandemic, published by the National Center of Biotechnology Information in 2021, reports a 3.5% decrease in the number of patients accessing eye care hospitals. Numerous ophthalmologists had to temporarily close their practices as a result of the pandemic.
Myasthenia Gravis Treatment Market Report Coverage:
| Report Attributes | Report Details |
| Study Timeline | 2016-2030 |
| Market Size in 2030 (USD Billion) | 4.23 Billion |
| CAGR (2022-2030) | 8.1% |
| By Treatment | Medication, Surgery, Others |
| By End Use | Hospitals, Clinics, Others |
| By geography | North America– (U.S., Canada, Mexico)
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe) Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific) Latin America- (Brazil, Argentina, Chile, Rest of Latin America) The Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA) |
| Key Players | Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc. Alexion Pharmaceuticals and Astellas Pharma |
Myasthenia Gravis Treatment Market Segment Analysis:
By Treatment
Medication has the largest market share among the treatments and is anticipated to hold the top spot throughout the projected period. This is due to drugs can significantly restrict the immune system while also managing the related symptoms. Corticosteroids, immunosuppressive pharmaceuticals like Prograf (tacrolimus), Neoral/Sandimmune, and immunotherapies like Soliris (eculizumab) are some examples of medications (cyclosporine). The most invasive kind of treatment is surgery, which is the other main option, and it typically entails a thymectomy (thymus removal). The thymus weakens with age (thymic involution), but its total loss in this way would seriously impair the immune system of the patient.
By End Use
The myasthenia gravis treatment market based on end-use has been divided into hospitals, clinics, and other entities. In 2021 the hospital sector had the largest market share, and during the projected period it is anticipated to grow at the highest CAGR. This can be attributable to access to a large patient pool and significant demand for modern equipment for MG treatment in hospital settings. The availability of a wide variety of treatment choices in such institutions has led to an increase in the frequency of patient visits for the diagnosis and treatment of MG. The increased investment in cutting-edge healthcare infrastructure is also one of the main drivers behind its huge share.
By Region
The regional segment includes Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. North America had the highest market share in 2021 and is anticipated to continue to dominate the market during the forecast period. This is explained by the widespread use of immunotherapies and monoclonal antibodies, rising healthcare costs, the presence of well-established institutions for research and development, and a favorable reimbursement environment.
Myasthenia Gravis Treatment Market Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Further, the surge in Research and Development (R&D), product innovation, various business strategies, and Treatment & Service launches have accelerated the growth of the myasthenia gravis treatment market. Key players in the market include-
- Alexion Pharmaceutical Inc.
- Grifols SA
- Avadel Pharmaceuticals plc.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Bausch Health Companies Inc.
- Shire plc. Alexion Pharmaceuticals
- Astellas Pharma
Table of Content
- Introduction
- Market Introduction
- Market Research Methodology
- Research Process
- Primary Research
- Secondary Research
- Data Collection Technique
- Data Sources
- Market Estimation Methodology
- Limitations of the Study
- Treatment Picture of Myasthenia Gravis Treatment
- Global Myasthenia Gravis Treatment Market: Classification
- Geographic Scope
- Years Considered for the Study
- Research Methodology in brief
- Parent Market Overview
- Overall Myasthenia Gravis Treatment Market Regional Demand
- Research Programs/Design
- Market Breakdown and Data Triangulation Approach
- Data Source
- Secondary Sources
- Primary Sources
- Primary Interviews
- AverEnd Use primary breakdown ratio
- Market Dynamics
- Drivers
- Drivers
- Restraints
- Restraints
- Opportunity
- Impact forces on market dynamics
- Impact forces during the forecast years
- Industry Value Chain
- Upstream analysis
- Downstream analysis
- Therapeutic
- Direct Channel
- Indirect Channel
- Potential Customers
- Manufacturing/Operational Cost Analysis
- Pricing Analysis by Region
- Key Treatment Landscape
- Regulatory Analysis
- Porter’s Analysis
- Supplier Power
- Buyer Power
- Substitution Threat
- Threat from New Entry
- Competitive Rivalry
- PESTEL Analysis
- Political Factors
- Economic Factor
- Social Factors
- Technological Factor
- Environmental Factors
- Legal Factor
- Covid-19 impact on Global Economy
- Covid-19 impact on Myasthenia Gravis Treatment Market demand
- Post-Covid Impact on Myasthenia Gravis Treatment Market Demand
- Impact Analysis of Russia-Ukraine Conflict
- Drivers
- Global Myasthenia Gravis Treatment Market Segmentation, Revenue (USD Billion), (2022-2030)
- By Treatment
- Medication
- Surgery
- Others
- By End Use
- Hospitals
- Clinics
- Others
- By Treatment
- By Global Myasthenia Gravis Treatment Market Overview, By Region
- North America Myasthenia Gravis Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- US
- By Treatment
- By End Use
- Canada
- Mexico
- US
- Europe Myasthenia Gravis Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Asia Pacific Myasthenia Gravis Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- China
- Japan
- Australia
- South Korea
- India
- ASEAN
- North America Myasthenia Gravis Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- Latin America Myasthenia Gravis Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- Brazil
- Argentina
- Chile
- Middle East and Africa Myasthenia Gravis Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- GCC
- Turkey
- South Africa
- Global Myasthenia Gravis Treatment Market Revenue: Competitive Analysis, 2021
- Key strategies by players
- Revenue (USD Billion and %), By manufacturers, 2021
- Player Positioning by Market Players, 2021
- Competitive Analysis
- Alexion Pharmaceutical Inc.
- Business Overview
- Business Financials (USD Billion)
- Treatment Category, Source, and Specification
- Main Business/Business Overview
- Geographical Analysis
- Recent Development
- Swot Analysis
- Grifols SA
- Avadel Pharmaceuticals plc. Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Bausch Health Companies Inc.
- Shire plc. Alexion Pharmaceuticals
- Astellas Pharma
- Alexion Pharmaceutical Inc.
- Market Research Findings & Conclusion
Disclaimer
Research Methodology
The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.